Related Experiment Video
Updated: May 15, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
CTLA-4 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.
1Shanghai Institute of Orthopaedics and Traumatology, Department of Orthopaedics, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Genetic Testing and Molecular Biomarkers
|January 8, 2013
Summary
This meta-analysis found no significant association between CTLA-4 gene polymorphisms (+49A/G and CT60A/G) and systemic lupus erythematosus (SLE) susceptibility. Further research is needed to explore other CTLA-4 variants and their role in SLE.
Area of Science:
- Immunogenetics
- Autoimmune Diseases
- Genetic Epidemiology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a significant genetic component.
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) plays a crucial role in regulating T-cell responses, making it a candidate gene for autoimmune diseases.
Purpose of the Study:
- To investigate the association between two single nucleotide polymorphisms (SNPs) in the CTLA-4 gene, specifically +49A/G and CT60A/G, and the susceptibility to systemic lupus erythematosus (SLE).
- To perform a comprehensive meta-analysis to consolidate existing evidence on these genetic variants and SLE risk.
Main Methods:
- A meta-analysis was conducted using data from 1753 SLE cases and 2279 controls for the +49A/G polymorphism.
- A separate meta-analysis included 676 SLE cases and 576 controls for the CT60A/G polymorphism.
- Allelic and genotypic comparisons were performed, with the +49A/G polymorphism further analyzed across Asian and European populations.
Main Results:
- The meta-analysis revealed no statistically significant association between the CTLA-4 +49A/G polymorphism and SLE susceptibility in the overall population or when stratified by Asian and European subgroups.
- Similarly, the CTLA-4 CT60A/G polymorphism did not show a significant association with SLE risk in the evaluated cohorts.
- Odds ratios and 95% confidence intervals did not indicate a significant contribution of these specific CTLA-4 SNPs to SLE pathogenesis.
Conclusions:
- The findings suggest that the investigated CTLA-4 gene polymorphisms (+49A/G and CT60A/G) are not significantly associated with susceptibility to systemic lupus erythematosus.
- Further research is warranted to explore other potential risk polymorphisms within the CTLA-4 gene.
- Clarifying the precise role of CTLA-4 in SLE pathogenesis requires investigation of additional genetic factors and functional studies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...